P/E ratio for RadNet (RDNT)
P/E ratio as of April 2024 (TTM): -212
According to RadNet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -212.304. At the end of 2022 the company had a P/E ratio of 105.
P/E ratio history for RadNet from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 105 | 63.29% |
| 2021 | 64.1 | -198.21% |
| 2020 | -65.2 | -193.19% |
| 2019 | 70.0 | 361.16% |
| 2018 | 15.2 | -100% |
| 2017 | > 1000 | 9.5909216250482E+17% |
| 2016 | 37.9 | 4.37% |
| 2015 | 36.4 | -87.23% |
| 2014 | 285 | 922.75% |
| 2013 | 27.8 | 1634.97% |
| 2012 | 1.60 | -85.69% |
| 2011 | 11.2 | -239.14% |
| 2010 | -8.06 | -76.3% |
| 2009 | -34.0 | 326.27% |
| 2008 | -7.98 | -64.64% |
| 2007 | -22.6 | 7.41% |
| 2006 | -21.0 | 561.11% |
| 2005 | -3.18 | 115.76% |
| 2004 | -1.47 | -84.23% |
| 2003 | -9.33 | 203.88% |
| 2002 | -3.07 | -182.35% |
| 2001 | 3.73 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Quest Diagnostics
DGX | 20.2 | -109.52% | 🇺🇸 USA |
 LabCorp LH | 27.7 | -113.03% | 🇺🇸 USA |
 Psychemedics PMD | -7.58 | -96.43% | 🇺🇸 USA |
 Enzo Biochem ENZ | -1.16 | -99.45% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.